drugset / Trial / NCT07525986

Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery

NCT07525986

Phase 4 Recruiting 140 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Visceral pain following laparoscopic surgery is frequently underestimated, yet it is associated with a range of adverse outcomes. Effective visceral pain management should constitute an essential component of postoperative analgesic strategies following laparoscopic procedures. However, conventional analgesic agents, including μ-opioid receptor agonists, lack specificity for visceral pain. Anrikefon, a novel selective peripheral κ-opioid receptor agonist, demonstrates unique efficacy in alleviating visceral pain with a favorable safety profile. Preliminary studies showed that a single intravenous dose of anrikefon effectively alleviates postoperative pain after abdominal surgery with a low risk of adverse effects. The investigators hypothesize that an appropriate dosing regimen of anrikefon administered via patient-controlled intravenous analgesia (PCIA) pump, as part of a multimodal analgesic strategy, can specifically target and alleviate visceral pain after laparoscopic surgery, thereby achieving comprehensive postoperative analgesia.

Timeline

Start
2026-04-14
Primary completion
2027-03
Completion
2027-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anrikefon Unknown 500 ug Intravenous
Subject Anrikefon Unknown 750 ug Intravenous
Subject Anrikefon Unknown 1000 ug Intravenous
Comparator Morphine Other / unclassified 50 mg Intravenous

Indications

No indication recorded.